Cellectis (NASDAQ:CLLS) Rating Lowered to “Hold” at StockNews.com

Cellectis (NASDAQ:CLLS) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

Cellectis Stock Performance

Shares of CLLS stock traded up $0.04 during mid-day trading on Wednesday, reaching $1.31. The stock had a trading volume of 222,188 shares, compared to its average volume of 137,466. The firm has a market cap of $72.82 million, a price-to-earnings ratio of -1.01 and a beta of 3.27. Cellectis has a 1-year low of $1.14 and a 1-year high of $3.38. The business’s fifty day moving average is $1.48 and its 200-day moving average is $1.79. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.22). The company had revenue of $33.22 million for the quarter, compared to analyst estimates of $5.90 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. On average, research analysts forecast that Cellectis will post -0.46 earnings per share for the current year.

Institutional Trading of Cellectis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in Cellectis by 103.4% during the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 12,500 shares during the period. Millennium Management LLC purchased a new position in Cellectis during the fourth quarter worth approximately $962,000. Finally, B Group Inc. purchased a new position in Cellectis during the fourth quarter worth approximately $5,547,000. 63.90% of the stock is owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.